Inotrem
Paris, FR· latest recorded location
INOTREM is named on 3 US grants and 6 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 3
- Published applications
- 6
- Inventors
- 21
- Granted in 2026 so far
- 1
- Most recent grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 3 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 9 documents
Recent patents
- TREM-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease7 Jul 2026US 12,673,083 B2
- Method for treating septic shock22 Jul 2025US 12,364,733 B1
- Methods and kits for predicting the risk of having a cardiovascular disease or event16 Mar 2021US 10,948,498 B2
- Anti-trem-1 antibodies1 Aug 2024US 2024/0254225 A1
- Soluble trem-1 as a marker of severity or complications for a subject suffering from a coronavirus infection31 Aug 2023US 2023/0273208 A1
- Trem-1 inhibitor for use in the treatment of a subject suffering from a coronavirus infection29 Jun 2023US 2023/0201301 A1
- Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease19 Jan 2023US 2023/0016187 A1
- Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy25 Nov 2021US 2021/0364532 A1
Most cited
By later US patents